

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1-40 (Cancelled)

41. (Currently amended) ~~A The protein variant according to claim 38, wherein:~~  
~~the CNTF, EPO, Flt3L, G-CSF, GH, IL 4, IL 6, IL 12p35, LPT, LIF, OSM, PL, and of~~  
~~TPO are wild type and are altered by substituting comprising an amino acid substitution of a~~  
~~valine residue for a phenylalanine residue of in at least one of the phenylalanine amino acid~~  
~~residues at between positions 110 to 180; and 128, 131 46, 128 and 131 of SEQ ID NO.:25~~  
~~the IFN  $\alpha$ 2A, IFN  $\alpha$ 2B, IFN  $\beta$ , IFN  $\gamma$ , IFN  $\omega$  and IFN  $\tau$  are wild type and are altered by~~  
~~substituting a valine residue for a phenylalanine residue of amino acid residues between~~  
~~positions 1 to 50.~~
42. (Currently Amended) The protein variant according to claim 41, wherein:  
~~the CNTF is altered by substituting a valine residue for a phenylalanine residue at~~  
~~position 119, 152 or 178 of an amino acid sequence designed as SEQ ID NO.:1;~~  
~~the EPO is altered by substituting a valine residue for a phenylalanine residue at position~~  
~~138, 142 or 148 of an amino acid sequence designed as SEQ ID NO.:2;~~  
~~the G-CSF is altered by substituting a valine residue for a phenylalanine residue at~~  
~~position 116, 143, 147 or 163 of an amino acid sequence designed as SEQ ID NO.:4;~~  
~~the GM-CSF is altered by substituting a valine residue for a phenylalanine residue at~~  
~~position 103, 106, 113 or 119 of an amino acid sequence designed as SEQ ID NO.:5;~~  
~~the GH is altered by substituting a valine residue for a phenylalanine residue at position~~  
~~139, 146, 166, 176 or 191 of an amino acid sequence designed as SEQ ID NO.:6;~~  
~~the IL 2 is altered by substituting a valine residue for a phenylalanine residue at position~~  
~~42 or 44 of an amino acid sequence designed as SEQ ID NO.:13;~~  
~~the IL 3 is altered by substituting a valine residue for a phenylalanine residue at position~~  
~~107 or 113 of an amino acid sequence designed as SEQ ID NO.:14;~~  
~~the IL 4 is altered by substituting a valine residue for a phenylalanine residue at position~~

~~112 of an amino acid sequence designed as SEQ ID NO.:15;~~  
~~—— the IL 5 is altered by substituting a valine residue for a phenylalanine residue at position~~  
~~69 of an amino acid sequence designed as SEQ ID NO.:16;~~  
~~—— the IL 6 is altered by substituting a valine residue for a phenylalanine residue at position~~  
~~124 of an amino acid sequence designed as SEQ ID NO.:17;~~  
~~—— the IL 12p35 is altered by substituting a valine residue for a phenylalanine residue at~~  
~~position 180 of an amino acid sequence designed as SEQ ID NO.:18;~~  
~~—— the LPT is altered by substituting a valine residue for a phenylalanine residue at position~~  
~~41 or 92 of an amino acid sequence designed as SEQ ID NO.:19;~~  
~~—— the LIF is altered by substituting a valine residue for a phenylalanine residue at position~~  
~~156 of an amino acid sequence designed as SEQ ID NO.:20;~~  
~~—— the M CSF is altered by substituting a valine residue for a phenylalanine residue at~~  
~~position 311 of an amino acid sequence designed as SEQ ID NO.:21;~~  
~~—— the OSM is altered by substituting a valine residue for a phenylalanine residue at position~~  
~~160 or 169 of an amino acid sequence designed as SEQ ID NO.:22;~~  
~~—— the PL is altered by substituting a valine residue for a phenylalanine residue at position~~  
~~166 or 176 of an amino acid sequence designed as SEQ ID NO.:23;~~  
~~—— the SCF is altered by substituting a valine residue for a phenylalanine residue at position~~  
~~199, 205 or 207 of an amino acid sequence designed as SEQ ID NO.:24;~~  
the TPO is altered by substituting a valine residue for a phenylalanine residue at position  
131 of an amino acid sequence designed as SEQ ID NO.:25;  
~~—— the IFN  $\alpha$ 2A is altered by substituting a valine residue for a phenylalanine residue at~~  
~~position 27, 36 or 38 of an amino acid sequence designed as SEQ ID NO.:7;~~  
~~—— the IFN  $\alpha$ 2B is altered by substituting a valine residue for a phenylalanine residue at~~  
~~position 27, 36 or 38 of an amino acid sequence designed as SEQ ID NO.:8;~~  
~~—— the IFN  $\beta$  is altered by substituting a valine residue for a phenylalanine residue at~~  
~~position 38 of an amino acid sequence designed as SEQ ID NO.:9;~~  
~~—— the IFN  $\gamma$  is altered by substituting a valine residue for a phenylalanine residue at position~~  
~~32 of an amino acid sequence designed as SEQ ID NO.:10;~~  
~~—— the IFN  $\omega$  is altered by substituting a valine residue for a phenylalanine residue at~~  
~~position 27, 36 or 38 of an amino acid sequence designed as SEQ ID NO.:11; and~~

Appl. No. 10/519,390  
Amendment and Response dated December 3, 2008

~~the IFN  $\tau$  is altered by substituting a valine residue for a phenylalanine residue at position 39 of an amino acid sequence designed as SEQ ID NO.:12.~~

43-76 (Cancelled)

77. (Previously presented) A pharmaceutical composition comprising the protein variant of claim 41 and a pharmaceutically acceptable carrier.

78. (Previously presented) A pharmaceutical composition comprising the protein variant of claim 42 and a pharmaceutically acceptable carrier.